CAMP4 Therapeutics Corporation (CAMP) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.90 (+6.85% 1D, market cap $244.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAMP ranks #842 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAMP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VNDA (Vanda Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $244.9M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, CAMP leads on earnings multiple (N/A) while CAMP leads on capital efficiency (-35.0% ROIC).
Per CAMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736730), CAMP4 Therapeutics Corporation generated $3.5M in revenue (+436.5% YoY), -$80.4M in net income, and -$29.8M in free cash flow against $117.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 21% of 52W Range • RSI-14 at 58.9 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CAMP currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.89) and Max Pain ($4.10) forces dealer call-delta covering toward $8.14.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
CAMP4 Therapeutics Corporation (CAMP) surged +6.85% to $3.90, trading at 21% of its 52-week range ($2.9 – $7.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to initiat
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company on track to
Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
Korro and Tevard outlined approaches designed to expand the therapeutic use of RNA medicines beyond protein silencing, highlighting programs that aim to repair genetic defects or restore production of full-length protein
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CAMP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CAMP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, CAMP4 Therapeutics Corporation (CAMP) ranks #842 by composite RQD confidence (34/100, grade E) and #552 by equity capitalization ($244.7M). Within this direct 5-issuer industry benchmark cohort, CAMP leads on earnings valuation at N/A trailing P/E, while CAMP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CAMP at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CAMP
ACTIVE
CAMP4 Therapeutics Corporation | E | 34/100 | — | — | -35.0% | +6.85% | $244.7M | Benchmark Subject |
| VNDA Vanda Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +1.25% | $244.9M | /vnda-vs-camp → |
| LFCR Lifecore Biomedical Inc. | D | 51/100 | — | — | — | +0.15% | $246.8M | /lfcr-vs-camp → |
| ELDN Eledon Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +10.15% | $247.0M | /eldn-vs-camp → |
| EVMN Evommune Inc. | D- | 43/100 | — | — | -35.0% | +7.92% | $247.1M | /evmn-vs-camp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CAMP4 Therapeutics Corporation (CAMP) reported GAAP revenue of $3.5M (+436.5% vs. FY2024 revenue of $652.0K , and +899.4% cumulative change since FY2023) , GAAP net income of -$80.4M, operating cash flow of -$29.6M, and free cash flow of -$29.8M (+35.2% YoY). On the balance sheet, CAMP closed FY2025 with $117.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.5M | -$80.4M | -$29.6M | -$29.8M | $117.8M | — |
| FY2024 (FY) | 2024-12-31 | $652.0K | -$51.8M | -$45.6M | -$46.0M | $78.3M | — |
| FY2023 (FY) | 2023-12-31 | $350.0K | -$49.3M | -$44.2M | -$44.2M | — | — |
As of 2026-11-01, CAMP4 Therapeutics Corporation (NASDAQ: CAMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.90 (+6.85% 1D, market cap $244.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAMP ranks #842 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAMP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VNDA (Vanda Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $244.9M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, CAMP leads on earnings multiple (N/A) while CAMP leads on capital efficiency (-35.0% ROIC).
Per CAMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736730), CAMP4 Therapeutics Corporation generated $3.5M in revenue (+436.5% YoY), -$80.4M in net income, and -$29.8M in free cash flow against $117.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CAMP last traded at $3.90 (+6.85% on volume of 151,983 shares), positioning the stock +0.26% above its 50-day simple moving average ($3.89) and -7.58% below its 200-day simple moving average ($4.22). Across its 52-week range of $2.90 to $7.75, CAMP sits at the 20.6% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.41 to $4.39).
Why CAMP Stock surged +6.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.